Pimobendan

Empirical Formula: C₁₉H₁₈N₄O₂
Molecular Weight: 334.3718
Nominal Mass: 334 Da
Average Mass: 334.3718 Da
Monoisotopic Mass: 334.142976 Da 
Index of Refraction: 1.692
Molar Refractivity: 94 cm³
Molar Volume: 245.2 cm³
Surface Tension: 51.7 dyne/cm
Density: 1.36 g/cm³
Structure of Pimobendan (CAS NO.74150-27-9):
                          
IUPAC Name: 3-[2-(4-Methoxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one
Canonical SMILES: CC1CC(=O)NN=C1C2=CC3=C(C=C2)N=C(N3)C4=CC=C(C=C4)OC
InChI: InChI=1S/C19H18N4O2/c1-11-9-17(24)22-23-18(11)13-5-8-15-16(10-13)21-19(20-15)12-3-6-14(25-2)7-4-12/h3-8,10-11H,9H2,1-2H3,(H,20,21)(H,22,24)
InChIKey: GLBJJMFZWDBELO-UHFFFAOYSA-N
Product Category of Pimobendan (CAS NO.74150-27-9): Pharmaceutical intermediates; cardiac drugs; cardiovascular drugs

 Pimobendan (CAS NO.74150-27-9) has strong positive inotropic effect and a strong vasodilator and platelet aggregation, and is used for the treatment of chronic and acute heart failure. It is used in the management of heart failure in dogs, most commonly caused by myxomatous mitral valve disease (also known as endocardiosis), or dilated cardiomyopathy.

 Pimobendan , its cas register number is 74150-27-9. It also can be called Pimobendane ; dl-Pimobendan ; and 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone . It is a positive inotrope, and sensitizes and increases the binding efficiency of cardiac myofibril to the calcium ions that are already present without increasing the consumption of oxygen and energy. It is metabolized into its active form by the liver, and is absorbed rapidly when given via the oral route and has a bioavailability of 60-65%.